Published in:
Open Access 01-02-2019 | Acromegaly
AcroVoice: eliciting the patients’ perspective on acromegaly disease activity
Published in: Pituitary | Issue 1/2019
Login to get accessAbstract
Purpose
To determine how patients define acromegaly disease activity and treatment success and to quantify from the patients’ perspective the relative importance of each disease parameter included in the ACRODAT®.
Methods
One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11.96) completed an online preference study evaluating hypothetical patient profiles described in terms of insulin-like growth factor-I (IGF-I) levels, tumor size, comorbid conditions, signs/symptoms, and quality of life (QoL). Participants first completed a single-profile task experiment by rating 20 single patient profiles as exhibiting stable, mild, or significant disease activity based on treatment success. Next, participants completed a double-profile discrete choice experiment (DCE) by selecting the patient that was doing “better” from 15 profile pairs. Results were analyzed using logistic and conditional logistic models.
Results
When choosing between stable vs. mild or significant disease activity, signs/symptoms, tumor size, and IGF-I levels were weighted equally; IGF-I and signs and symptoms were valued equally when selecting mild vs. significant disease activity. The DCE showed that, statistically, all disease parameters, except comorbid conditions, predicted health status equally. Tumor size and IGF-I levels each accounted for 23% of the decision-making process; QoL, signs/symptoms, and comorbid conditions accounted for 21%, 19%, and 14%, respectively.
Conclusion
All five ACRODAT® parameters had some influence on disease activity from the patients’ perspective. To account for patients’ preferences and optimize treatment and outcomes, a holistic disease management approach should be employed.